Ivo Stoilov, MD

Dr. Ivo Stoilov, MD is a Principal Medical Director, US Medical Affairs Ophthalmology, Genentech. He has served as a medical lead for LUCENTIS (ranibizumab injection), VABYSMO (faricimab-svoa) and currently for the IL-6 inhibitor Vamikibart. As an Assistant Professor at the Department of Pharmacology, University of Connecticut Health Center, Dr. Stoilov was a PI on grants funded by the National Eye Institute and the Sandler Program for Asthma Research. His work led to the discovery that Cytochrome P4501B1 mutations cause primary congenital glaucoma. Dr. Stoilov has published extensively in peer reviewed journals including JAMA and Nature Genetics, He obtained his MD degree from the Medical university, Sofia, Bulgaria and received postdoctoral training at the Molecular Ophthalmic Genetics Laboratory, UCONN Health Center.